4
Clinical Trials associated with Irinotecan Hydrochloride Lioposome(Qilu Pharmaceutical) / Not yet recruitingPhase 2IIT A Randomized, Open-Label, Multicenter Phase II Clinical Study of Long-Course Chemoradiotherapy Followed by NALIRIFOX as Total Neoadjuvant Therapy for Locally Advanced Low-Lying pMMR/MSS Rectal Cancer
/ RecruitingNot Applicable [Translation] Study on the bioequivalence of irinotecan liposome injection in healthy volunteers
研究单次静脉给予受试制剂伊立替康脂质体注射液与参比制剂伊立替康脂质体注射液(ONIVYDE®)在受试者体内的药代动力学,评估两种制剂的生物等效性和安全性。
[Translation] To study the pharmacokinetics of the test formulation irinotecan liposome injection and the reference formulation irinotecan liposome injection (ONIVYDE®) in subjects after a single intravenous administration and to evaluate the bioequivalence and safety of the two formulations.
/ Active, not recruitingPhase 1 一项盐酸伊立替康脂质体注射液在晚期实体瘤患者中的安全性、耐受性及药代动力学Ia期临床研究
[Translation] A Phase Ia clinical study on the safety, tolerability and pharmacokinetics of irinotecan hydrochloride liposome injection in patients with advanced solid tumors
本品拟考虑在晚期实体瘤患者中初步评价本品单药耐受性和药代动力学特征,观察主要不良反应和DLT,确定MTD,并初步观察有效性。
[Translation] This product is intended to be considered for preliminary evaluation of the monotherapy tolerability and pharmacokinetic characteristics of this product in patients with advanced solid tumors, to observe major adverse reactions and DLT, to determine the MTD, and to preliminarily observe the effectiveness.
100 Clinical Results associated with Irinotecan Hydrochloride Lioposome(Qilu Pharmaceutical)
100 Translational Medicine associated with Irinotecan Hydrochloride Lioposome(Qilu Pharmaceutical)
100 Patents (Medical) associated with Irinotecan Hydrochloride Lioposome(Qilu Pharmaceutical)
100 Deals associated with Irinotecan Hydrochloride Lioposome(Qilu Pharmaceutical)